Skip to NavigationSkip to content


NHS guidelines on prescription cannabis to be challenged in court

Photo by Cannabis Tours

The cannabis guidelines followed by the NHS are set to be challenged in court by the parents of a three-year-old boy with severe epilepsy.

Matt and Ali Hughes treat their son Charlie with cannabis oil, which they buy privately, and it has reduced their son’s seizures from 120 a day to fewer than 20. Previously, the couple had given Charlie six different types of anti-epileptic drugs but they saw no improvement in his condition.

UK Home office reclassifies Epidyolex as a Schedule 5 drug

Photo by Steve Cadman

The Home Office has announced that the drug Epidyolex (cannabidiol) has been reclassified as a Schedule 5 drug, a move from a Schedule 2 substance under the Misuse of Drugs Regulation 2001.

NHS to fast track cannabis-based treatment for epilepsy

The NHS has fast-tracked the drug Epidyolex, a cannabidiol (CBD), to be available for epilepsy treatment through the NHS in England, starting on 6 January 2020.

The drug had been recommend for use in treating two types of epilepsy, Lennox-Gastaut and Dravet syndromes, back in November.

Doctors will be able to prescribe the drug Epidyolex with clobazam for eligible children with this disease. Clinical trials have shown this treatment could reduce seizures of up to 40% in some children.

British Pharmacists call for regulation on non-medicinal CBD products

Pharmacists are calling for more checks on products containing Cannabis derivative cannabidiol (CBD) that are sold in shops across the country.

At the moment cannabidiol oil is classified as a food supplement, and it has been recently added to a range of products like chocolate, coffee, tea and makeup. It’s a brand-new type of food so there is a grace period where it is allowed to be sold in shops, but the Food Standards Agency (FSA) has now asked manufactures to give specific information about the product.

A new weapon against Parkinson’s-related psychosis

Published on 16/12/19 at 03:13pm

Dr Arthur Roach, Director of Research at the charity Parkinson's UK, discusses new trials on cannabidiol in the treatment of Parkinson’s-related psychosis and explains how they could potentially offer hope in improving patient’s lives in what is a seriously unmet need.

Can you tell us about the project and how it got started?

Up to 60% of people with Parkinson’s are affected by psychosis at some point while living with the condition but there are currently no medications licensed in the UK to address this distressing symptom.

NICE refuses GW Pharma's cannabis-based Epidyolex for treatment-resistant epilepsy

UK-based GW Pharma has suffered a setback in its home country after drug watchdog NICE chose not to recommend NHS reimbursement of Epidyolex (cannabidiol/CBD) in combination with clobazam for people with Dravet or Lennox-Gastaut syndrome (LGS), two forms of treatment-resistant epilepsy.

Despite concluding that the combo therapy effectively reduced the total number of the most prominent seizure types associated with these conditions compared to standard of care, the institute pointed to the lack of definitive long-term efficacy data, given that trial data submitted covered just 14 w

Hundreds of patients turn to private cannabis clinics in UK

Hundreds of people have turned to private clinics, in an effort to gain access to medicinal cannabis in the UK, according to the BBC.

While medicinal cannabis was made legal in Britain in November 2018, few patients have been able to access the drug on the NHS.

Patients are thus turning to private clinics, and paying as much as £800 a month, to get legal medicinal cannabis.

Medicinal cannabis company Spectrum makes first shipment into UK

Medicinal cannabis company Spectrum Europe has made its first shipment of cannabis into the UK, making it one of the first companies to successfully import legal medicinal cannabis into Britain.

In November 2018, the UK Government allowed doctors to prescribe unlicensed cannabis-based medicinal products to British patients with an unmet need that cannot be met by licensed products.

GW Pharma's cannabis-based Epidyolex edges closer to EU approval with positive CHMP opinion in epilepsy

UK-based biotech GW Pharmaceuticals has announced that its cannabidiol oral solution Epidyolex has secured recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The specialist panel chose to endorse the therapy and push for its approval, in combination with clobazam, as an adjunctive treatment for seizures associated with Lennox‑Gastaut syndrome (LGS) or Dravet syndrome in patients at least two years old.

Top Ten most popular articles on this week!

The top story of this week covered Novartis’ announcement that they did not send chemicals that could be used to make chemical weapons to Syria. The announcement came as a relief to shareholders as shares in chemical distributor Brenntag plummeted after it was found they had send chemical weapon precursors to the war torn country.  

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches